38025-90-0

Basic information

• Product Name: 2-Chloro-6-hydroxynicotinic acid
• Synonyms: 2-Chloro-6-Hydroxynicotinic Acid;2-CHLORO-6-HYDROXYNICOTINIC ACID,98%;2-Chloro-6-hydroxy-3-pyridinecarboxylic Acid;2-Chloro-6-hydroxypyridine-3-carboxylic acid
• CAS NO: 38025-90-0
• Molecular Formula: C6H4ClNO3
• Molecular Weight: 173.55
• Product Categories: pharmacetical;API intermediates
• Mol File: 38025-90-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 302°C(lit.)
• Boiling Point: 486.65 °C at 760 mmHg
• Flash Point: 248.117 °C
• Appearance: /
• Density: 1.644 g/cm³
• Vapor Pressure: 2.77E-10mmHg at 25°C
• Refractive Index: 1.64
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-Chloro-6-hydroxynicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-6-hydroxynicotinic acid(38025-90-0)
• EPA Substance Registry System: 2-Chloro-6-hydroxynicotinic acid(38025-90-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 38025-90-0(Hazardous Substances Data)

Usage

Chemical Properties

Off-white powder

InChI:InChI=1/C6H4ClNO3/c7-5-3(6(10)11)1-2-4(9)8-5/h1-2H,(H,8,9)(H,10,11)

Upstream product

• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 262423-77-8 2,4-dichloronicotinic acid 

Downstream Products

• 934639-06-2 2-(2-fluoro-4-iodophenylamino)-1,5-dimethyl-6-oxo-N-(2-(vinyloxy)ethoxy)-1,6-dihydropyridine-3-carboxamide 
• 869357-68-6 2-[(2-fluoro-4-iodoiodophenyl)amino]-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide 
• 869357-67-5 2-(2-fluoro-4-iodo-anilino)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid methyl ester 
• 869357-63-1 methyl 5-bromo-2-chloro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 

Relevant articles and documents

Compound with cell proliferative resistance activity, preparation method and application

The invention relates to a compound with cell proliferative resistance activity, a preparation method and application. The invention discloses a compound with cell proliferative resistance activity, as shown in formula I, pharmaceutically acceptable salt

COMBINATION THERAPY COMPRISING AZD2171 AND AZD6244 OR MEK-INHIBITOR II

The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of AZD2171 in combination with AZD6244 or MEK Inhibitor II; to a pharmaceutical composition comprising AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II; to a combination product comprising AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II for use in a method of treatment of a human or animal body by therapy; to a kit comprising AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II; to the use of AZD2171 and AZD6244 or AZD2171 and MEK Inhibitor II in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.

HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF

Disclosed are MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.